Table 2 Treatment outcomes by response group.
Responders (n = 36) | Non-Responders (n = 34) | P-value | |
|---|---|---|---|
Treatment distribution | |||
PDT, n (%) | 9 (25.0) | 11 (32.4) | 0.742 |
Eplerenone, n (%) | 9 (25.0) | 7 (20.6) | |
SMLT, n (%) | 18 (50.0) | 16 (47.1) | |
BCVA (decimal) | |||
Baseline | 0.52 ± 0.14 | 0.51 ± 0.15 | 0.845 |
Final | 0.85 ± 0.12 | 0.45 ± 0.18 | <0.001 |
Within-group p-value | <0.001 | 0.042 | |
Sattler’s layer foci | |||
Baseline | 57.78 ± 31.79 | 55.12 ± 21.07 | 0.674 |
Final | 48.61 ± 24.00 | 59.74 ± 22.78 | 0.043 |
Within-group p-value | 0.001 | 0.041 | |
Haller’s layer foci | |||
Baseline | 7.47 ± 10.17 | 7.91 ± 8.98 | 0.854 |
Final | 4.28 ± 7.03 | 7.97 ± 10.96 | 0.047 |
Within-group p-value | 0.039 | 0.972 | |
Central retinal thickness (μm) | |||
Baseline | 417.86 ± 133.48 | 408.54 ± 128.76 | 0.765 |
Final | 245.32 ± 45.67 | 385.45 ± 112.34 | <0.001 |
Within-group p-value | <0.001 | 0.042 | |
Choroidal thickness (μm) | |||
Baseline | 418.47 ± 98.31 | 422.35 ± 102.44 | 0.872 |
Final | 385.24 ± 88.45 | 428.67 ± 98.76 | 0.045 |
Within-group p-value | 0.028 | 0.782 | |
SHRM resolution, n (%) | 14/18 (77.8) | 6/19 (31.6) | 0.002 |
pMA development, n (%) | 4 (11.1) | 11 (32.4) | 0.001 |
pMA Developed (n = 15) | No pMA (n = 55) | ||
Baseline total HCF count | 89.26 ± 42.15 | 61.62 ± 35.48 | 0.089 |
Final total HCF count | 94.36 ± 46.82 | 53.63 ± 26.48 | 0.003 |
